Adapting Stimulant Care for Psychiatric Conditions in CO

Adapting stimulant treatment for psychiatric conditions means adjusting recommended behavioral care to account for how both conditions affect each other. When an integrated behavioral intervention is unavailable, the ASAM/AAAP stimulant treatment guideline recommends this tailored approach. Psychiatric treatment still needs its own place in the plan.

You should not have to treat depression, anxiety, or another psychiatric condition as irrelevant to stimulant recovery. Yet one combined intervention may not be available. Recommendation 22 gives clinicians an alternative: use recommended stimulant behavioral treatments while addressing possible interactions with the other condition. That is different from offering an unchanged substance-focused intervention and hoping psychiatric symptoms resolve. It also does not turn every stimulant counseling session into complete treatment for another disorder. The distinction matters because behavioral goals, psychiatric treatment, medication safety, and emergency needs can each require attention within a connected care plan.

What does the guideline recommend when an integrated intervention is unavailable?

The guideline recommends tailoring an established stimulant behavioral treatment to the interactions between stimulant use disorder and the co-occurring condition. Our explanation of co-occurring care versus substance-only programs provides the broader context. Within that scope, an approach such as CBT for stimulant use disorder can address stimulant-related patterns without treating psychiatric symptoms as a separate, irrelevant story. This fallback pathway comes directly from Recommendation 22.

The recommendation has two branches. When available, clinicians should use integrated behavioral treatment that addresses both conditions. Otherwise, they should adapt recommended stimulant behavioral therapy to address possible interactions. The second branch is an active treatment option, rather than an instruction to postpone all care until a particular combined intervention becomes available.

The surrounding guidance matters too. Recommendation 21 calls for treating stimulant use disorder and co-occurring disorders concurrently, meaning during the same period. Tailoring stimulant treatment does not cancel that responsibility. A psychiatric condition should not have to remain untreated while stimulant work proceeds.

There are evidence limits. The guideline rates Recommendation 22 as a strong recommendation supported by very-low-certainty evidence. Its discussion describes limited, varied studies, including research on mixed substance-use populations rather than stimulant use disorder alone. The recommendation supports a clinical pathway; it does not prove that every adaptation works equally well or matches every integrated intervention.

How is tailored stimulant treatment different from ignoring psychiatric needs?

Tailored treatment allows psychiatric needs to influence the stimulant work while preserving treatment for the psychiatric condition itself. That connection is central to Women’s Recovery’s description of substance use and mental health care and its outpatient program scope. The guideline’s fallback is narrower than a general promise of coordinated care: it concerns adapting the behavioral intervention itself.

Three related parts of care can overlap, but they answer different needs. The table separates their purposes. These are clinical distinctions, not three fixed program packages or claims that one professional must provide everything.

These distinctions follow Recommendations 21–25. The guideline also describes integrated care broadly, from coordinated concurrent care to skilled treatment of both conditions within one provider or program. A single named manual is therefore not the only way care can be connected.

Ignoring psychiatric needs would mean leaving them out of the stimulant intervention despite their relevance. Tailoring means the clinician considers how those needs affect the work. Completing a stimulant-focused goal does not, by itself, establish that depression, anxiety, or another condition has received enough treatment.

Which stimulant behavioral treatments can clinicians adapt?

Recommendation 22 names contingency management, cognitive behavioral therapy, and the community reinforcement approach as examples. Our explanations of stimulant-focused CBT and contingency management for stimulant use disorder describe two of those foundations. The guideline’s behavioral recommendations continue to apply when psychiatric conditions are present; tailoring is not permission to discard the evidence-based approach.

• Contingency management, or CM: This uses positive reinforcement for observable treatment behaviors. NIDA describes examples such as remaining drug-free or attending and participating in counseling. Tailoring requires considering how psychiatric symptoms interact with the treatment goals and participation. It does not mean treating a person’s mood as a simple reward target or assuming symptoms reflect unwillingness.
• Cognitive behavioral therapy, or CBT: NIDA describes substance-focused CBT as helping people recognize, avoid, and cope with situations in which drug use is likely. An adaptation can bring relevant psychiatric symptoms into that work. For example, a clinician might examine how anxiety enters a stimulant-use situation rather than discussing the situation without its emotional context. That illustration is not a prescribed anxiety exposure protocol.
• Community reinforcement approach, or CRA: The guideline identifies CRA as another recommended behavioral option and explicitly includes it among the examples in Recommendation 22. Its selection does not settle how a particular psychiatric condition should be treated. The clinician still needs to connect the stimulant intervention with that person’s psychiatric needs.

The descriptions of CM and CBT above are supported by NIDA’s explanation of behavioral addiction therapies. The guideline recommends CM as a primary component of stimulant treatment alongside other psychosocial treatments. Its examples of adaptation are not a requirement that every person receive all three approaches.

The treatment method should remain recognizable in purpose. A general conversation about feelings is not automatically adapted CBT, and ordinary encouragement is not automatically CM. The useful connection is between the method’s treatment task and the way the psychiatric condition affects that task.

What does addressing interactions between the conditions mean?

It means considering how psychiatric symptoms, stimulant use, and treatment responses may affect one another, without assuming one cause for everything. This builds on work on stimulant-related situations and responses while remaining alert to mood and sleep symptoms that need continued attention. Recommendation 24 specifically directs clinicians to consider symptom timing, severity, and duration.

Consider a hypothetical woman who experiences low mood before stimulant use and disturbed sleep afterward. A tailored behavioral intervention could examine the role low mood plays in the use pattern and how the aftermath affects her next choices. That does not establish that depression caused the stimulant use, or that stopping use will resolve every mood symptom.

Within clinician-led treatment, attention to interactions can include:

• The context before use: Psychiatric symptoms may be relevant to situations, thoughts, or feelings associated with stimulant use. Their role needs exploration rather than assumption.
• The pattern during and after use: Symptoms should be considered in relation to active use and withdrawal, as well as times outside those phases.
• The fit of the behavioral work: A coping response discussed in therapy needs to make sense in the circumstances where the person would use it.
• Needs that remain unresolved: Progress on stimulant-related goals should not make continuing psychiatric symptoms disappear from the plan.

These are illustrations of the recommendation’s purpose, not a validated checklist or a universal treatment sequence. NIDA advises tailoring treatment to the person’s drug-use patterns and related medical, mental, and social problems. The adaptation should serve that individual picture rather than force every woman through the same account of why she uses stimulants.

Which psychiatric needs remain beyond a stimulant behavioral intervention?

Psychiatric symptoms still require the treatment they warrant, including medication when indicated and urgent assessment when safety is at risk. Our discussions of psychosis after stimulant use and changing suicide risk as stimulants wear off explain why these concerns cannot be reduced to a counseling adjustment. Recommendations 23–25 preserve specific psychiatric treatment responsibilities.

The guideline calls for indicated medication treatment for symptoms of psychosis or mania. It also tells clinicians to consider medication for depression, anxiety, insomnia, or attention problems based on symptom severity and duration, even when symptoms may be stimulant-induced. A possible substance-related cause is not a reason to dismiss symptoms or leave them untreated.

For someone with an existing psychiatric diagnosis, the guideline recommends reviewing the current treatment plan and continuing medications as appropriate, with attention to safety during possible ongoing substance use. That is a clinical decision. Beginning adapted behavioral treatment is not an automatic reason to stop, replace, or change a psychiatric prescription.

The practical boundary is clear: adaptation changes how behavioral treatment addresses overlapping needs. It does not establish that behavioral treatment alone is sufficient for the psychiatric condition, and it does not make a lower-support setting appropriate during an emergency.

Does the recommendation confirm a particular program offers every approach?

No. A clinical recommendation does not guarantee that a particular program offers every approach. Women’s Recovery provides outpatient mental health, trauma, and substance-use care, including PHP and an Intensive Outpatient Program (IOP). Its substance-use care addresses substance use alongside mental health. PHP and IOP describe levels of outpatient structure, not a guarantee of every intervention named in Recommendation 22.

The treatment task is to connect a recommended stimulant behavioral approach with the ways your conditions interact. There is no single adaptation prescribed for everyone. CM, CBT, and CRA are examples clinicians can tailor, not services you should assume are included simply because a program offers PHP or IOP. Any separately indicated psychiatric treatment still needs to remain part of your plan.

Women’s Recovery provides outpatient care in Denver, CO, not onsite detox, residential, or inpatient treatment. To discuss the program’s actual scope, visit Women’s Recovery’s contact page or call 833.754.0554. The central treatment principle remains the same: when one integrated behavioral intervention is unavailable, recommended stimulant care can be tailored while psychiatric treatment and safety responsibilities remain in place.

Frequently asked questions

Does lacking one integrated intervention mean all treatment must wait?

No. Recommendation 22 provides an alternative when an integrated behavioral intervention is unavailable: clinicians should tailor recommended stimulant behavioral treatment to address possible interactions with the co-occurring condition. The guideline also recommends treating both conditions concurrently. Urgent medical or psychiatric needs still take priority over routine behavioral treatment.

Is an adapted stimulant intervention automatically a complete psychiatric treatment?

No. Adapting stimulant treatment means accounting for the other condition within the behavioral work. It does not establish that all psychiatric needs have been treated. Depression, anxiety, psychosis, mania, or other symptoms may require additional psychiatric treatment, including medication when indicated, based on an individual clinical review.

Does tailoring treatment mean abandoning evidence-based stimulant approaches?

No. The recommendation specifically calls for tailoring recommended stimulant behavioral therapies, with contingency management, cognitive behavioral therapy, and the community reinforcement approach given as examples. The aim is to address interactions with psychiatric conditions while retaining the treatment’s purpose. It is not permission to replace clinical treatment with unsupported coping advice.

Does this guideline recommendation confirm a specific combined therapy at Women’s Recovery?

No. The guideline describes a recommended clinical pathway, not the services of a particular program. Women’s Recovery confirms outpatient mental health, trauma, and substance-use programs. That scope does not establish availability of every named behavioral method, a specific combined manual, or every psychiatric adaptation discussed in general education.